Iris De Weerdt

Amsterdam, NH, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.

Journal: Cell reports. Medicine

Published: August 14, 2022

A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.

A Bispecific Single-Domain Antibody Boosts Autologous Vγ9Vδ2-T Cell Responses Toward CD1d in Chronic Lymphocytic Leukemia.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 24, 2020

A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.

A Bispecific Antibody Antagonizes Prosurvival CD40 Signaling and Promotes Vγ9Vδ2 T cell-Mediated Antitumor Responses in Human B-cell Malignancies.

Journal: Cancer immunology research

Published: February 13, 2020

Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL.

Functional Differences Between EBV- and CMV-Specific CD8+ T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL.

Journal: HemaSphere

Published: July 22, 2019

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling.

Journal: HemaSphere

Published: July 11, 2019

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment.

Journal: Blood advances

Published: April 26, 2019

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes.

Journal: Journal of immunology (Baltimore, Md. : 1950)

Published: March 18, 2019

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?

Journal: HemaSphere

Published: February 03, 2019

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.

Journal: Blood

Published: December 19, 2017

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach.

Journal: Haematologica

Published: January 11, 2017

Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia.

Innate lymphoid cells are expanded and functionally altered in chronic lymphocytic leukemia.

Journal: Haematologica

Published: September 24, 2016

From annual check-up to annual appraisal: personalised diabetes care

From annual check-up to annual appraisal: personalised diabetes care

Journal: Nederlands tijdschrift voor geneeskunde

Published: July 14, 2016

Showing 1-12 of 14

Last Updated: 09/26/2026